Aquestive Therapeutics Inc (AQST) is 22.01% away from 50-day simple Moving Average despite all headwinds

Aquestive Therapeutics Inc (NASDAQ: AQST) established initial surge of 5.80% at $4.38, before settling in for the price of $4.14 at the close. Taking a more long-term approach, AQST posted a 52-week range of $1.01-$6.23.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


The Healthcare sector firm’s twelve-monthly sales growth has been -4.81% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was 46.61%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -187.91%. This publicly-traded company’s shares outstanding now amounts to $89.97 million, simultaneously with a float of $83.74 million. The organization now has a market capitalization sitting at $394.07 million. At the time of writing, stock’s 50-day Moving Average stood at $3.63, while the 200-day Moving Average is $2.27.

Aquestive Therapeutics Inc (AQST) Ownership Facts and Figures

Sometimes it is also beneficial to study the sentiment of large-scale investors towards the stock of the Aquestive Therapeutics Inc industry. Aquestive Therapeutics Inc’s current insider ownership accounts for 6.92%, in contrast to 26.45% institutional ownership. According to the most recent insider trade that took place on Mar 15 ’24, this organization’s Chief Innovation/Tech Officer sold 50,000 shares at the rate of 6.00, making the entire transaction reach 300,000 in total value, affecting insider ownership by 984,476. Preceding that transaction, on Mar 08 ’24, Company’s Chief Innovation/Tech Officer sold 25,000 for 5.19, making the whole transaction’s value amount to 129,685. This particular insider is now the holder of 1,040,371 in total.

Aquestive Therapeutics Inc (AQST) Earnings and Revenue Records

Going through the last 3-months fiscal report unveiled on the 12/30/2023, it has been observed that the corporation posted -$0.12 earnings per share (EPS) during the time that was less the consensus figure (set at -$0.08) by -$0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.09 per share during the current fiscal year.

Aquestive Therapeutics Inc’s EPS decrease for this current 12-month fiscal period is -187.91% and is forecasted to reach -0.30 in the upcoming year.

Aquestive Therapeutics Inc (NASDAQ: AQST) Trading Performance Indicators

Let’s observe the current performance indicators for Aquestive Therapeutics Inc (AQST). It’s Quick Ratio in the last reported quarter now stands at 1.87. The Stock has managed to achieve an average true range (ATR) of 0.46. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 7.79.

In the same vein, AQST’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.14, a figure that is expected to reach -0.08 in the next quarter, and analysts are predicting that it will be -0.30 at the market close of one year from today.

Technical Analysis of Aquestive Therapeutics Inc (AQST)

Now, what If we examine the latest scores posted by [Aquestive Therapeutics Inc, AQST]. During the last 5-days, its volume was better the volume of 2.14 million it reported in year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 32.32% While, its Average True Range was 0.44.

Raw Stochastic average of Aquestive Therapeutics Inc (AQST) in the period of the previous 100 days is set at 60.47%, which indicates a major rise in contrast to 17.41% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 111.32% that was higher than 93.88% volatility it exhibited in the past 100-days period.